Drug Discovery and Development — Comprehensive Study Notes

What is a Drug?

• Definition: Any substance, other than food or nutrients, used to prevent, diagnose, treat, or alleviate the symptoms of a disease or an ailment, often by affecting specific biological processes.

• Prophylactic: A treatment that prevents disease or slows its progression (e.g., folic acid for prevention of anemia, vaccines for infectious diseases). These aim to avert the onset of illness.

• Therapeutic: A treatment that helps with a disease or condition by directly addressing its cause or progression (e.g., Chemotherapy for cancer, antibiotics for bacterial infections).

• Symptomatic: A treatment that reduces symptoms but doesn't change the underlying disease (e.g., paracetamol for relieving fever, pain relievers for headaches). Focuses on improving comfort.

• Disease modifying: A treatment that changes the underlying disease process, potentially slowing or reversing disease progression (e.g., Leflunomide is an immunosuppressive for rheumatoid arthritis, statins for cardiovascular disease).

• Origin: Drugs can be Synthetic (chemically synthesized in labs), Naturally derived (extracted from plants, animals, or microorganisms), or Biologics (large complex molecules produced in living systems, like antibodies or proteins).

  • Examples: Paracetamol (synthetic origin); Morphine (natural origin; from the Opium poppy, Papaver somniferum).

Drug Discovery and Development

• Drug discovery: The intricate process of identifying new chemical entities or biological molecules with the potential to treat or cure diseases. This involves understanding disease mechanisms, identifying targets, and finding compounds that interact with these targets.

• Drug development: The subsequent rigorous process of taking those potential treatments through extensive preclinical testing and regulatory approval to become clinically available medicines. It focuses on safety, efficacy, and optimal formulation.

• Importance: This combined effort drives medical innovation, advances treatment options for debilitating diseases, significantly improves patient outcomes, extends life expectancy, and addresses critical unmet medical needs globally.

Drug Discovery Phase vs Drug Development Phase (Summary)

• Drug Discovery Phase

  • Activities: Target identification and validation (understanding disease pathways); Hit identification (screening large libraries via High-Throughput Screening (HTS) or virtual screening); Lead optimization (improving potency, selectivity, and physicochemical properties); Early toxicology (initial assessment of toxicity in in vitro and in vivo models); Potency/efficacy studies (how well a compound works at a given dose); Pharmacokinetics (ADME: Absorption, Distribution, Metabolism, Excretion studies); Screening in animal models for proof-of-concept.

  • Success rate: $2\%-5\%$

  • Cost: $\sim 5\times 10^{8} \text{ USD}$

  • Duration: $3-5\text{ years}$

• Drug Development Phase

  • Activities: Extensive toxicology studies (long-term animal studies to establish safety profiles); Clinical trials (Phase 0–III in human volunteers and patients); Regulatory submissions (preparing comprehensive dossiers like New Drug Applications (NDAs) to agencies); Drug approval (based on demonstrated safety and efficacy); GMP-based scale-up production & formulation (manufacturing processes ensuring quality and consistency).

  • Success rate: $5\%-20\%$

  • Cost: $\sim 5\times 10^{8} \text{ USD}$

  • Duration: $4-6\text{ years}$

• Overall perspective: Historically, the entire process spans long timelines with substantial risk and cost, making it one of the most challenging and expensive endeavors in scientific research and industry.

Historical Context

• Pre-industrial drug discovery was deeply rooted in observation of nature, focusing on plants and traditional remedies used across diverse cultures.

• 7000–5500 BC: Betel nut seeds found in Spirit Caves (northern Thailand); used as a mild psychoactive agent for its stimulating effects.

• 7000–5000 BC: Hallucinogenic mushroom use strongly implicated by detailed Saharan cave drawings, suggesting early spiritual or medicinal applications.

• 2680 BC: Lime-containing betel nut shells found in Duyong cave, Philippines; historically used in traditional medicine in India and Southeast Asia for its medicinal properties.

• Alcohol has been widely used by various civilizations for both recreational purposes and its perceived medicinal properties, including as an anesthetic, antiseptic, and social lubricant.

Early Documented Evidences

• Treatise of Medical Diagnosis and Prognoses (Mesopotamia, $\sim1700\text{ BC}$): One of the earliest medical texts, detailing diagnostic methods, prognoses, and specific medical prescriptions inscribed on stone tablets, reflecting a systematic approach to illness.

• Ebers Papyrus (ancient Egypt, $\sim1550\text{ BC}$): An extensive medical papyrus containing hundreds of prescriptions, spells, and remedies for specific disease treatments or symptomatic relief, showcasing a rich pharmacopeia that included plant, animal, and mineral substances.

• Charaka Samhita (Ayurveda founder, India, predates $\sim100\text{ AD}$): A foundational text in Ayurvedic medicine, which emphasizes holistic healing, health preservation, disease prevention, and individualized treatments based on body types and natural balances.

Basic Principles of Pre-historic Drug Discovery

• Heavily plant-based: Reliance on naturally occurring plant-derived mixtures or extracts, often passed down through generations of healers and shamans, due to direct availability and observed effects.

• Empirical observations: Treatments were chosen primarily based on observed symptom relief, trial and error, or anecdotal evidence rather than a deep understanding of underlying disease mechanisms or pharmacological actions.

• Limited fundamental knowledge: Disease progression, human physiology, and pharmacology were not well understood, leading to a focus on symptomatic relief rather than curative approaches or dosage standardization. The concept of specific chemical compounds was yet to emerge.

Discovery of Quinine

• Agostino Salumbrino (1561–1642), a Jesuit missionary, observed the Quechua people in Peru chewing cinchona bark to relieve shivering and fevers associated with malaria.

• Cinchona bark extracts were subsequently shown to effectively affect the febrile phase of malaria; samples were shipped to Rome for further evaluation by European physicians.

• Outcome: Quinine, the active compound isolated from cinchona bark, became the first successful antimalarial agent and served as a first-line treatment for malaria worldwide until approximately 2006, when resistance issues led to its replacement by newer drugs. Its discovery marked a significant step in evidence-based medicine.

The Big Picture

• Drug discovery is the cornerstone of medical innovation, constantly seeking new ways to combat disease and improve health.

• Global impact: It profoundly improves life expectancy, enhances overall quality of life for millions, and generates significant economic benefits through advances in healthcare industries.

• Intersection of science, medicine, and business: This field requires rigorous scientific research, clinical expertise, and substantial financial investment, highlighting its complex multidisciplinary nature.

• Continuous cycle of innovation: The ongoing emergence of new diseases, antibiotic resistance, and evolving health challenges necessitate a continuous and adaptive cycle of research and development.

Key Objectives

• Develop safe and effective treatments for diseases: The primary goal, ensuring therapeutic benefits outweigh potential risks.

• Address unmet medical needs and rare diseases: Focusing resources on conditions with limited or no current treatment options, often involving incentives for orphan drug development.

• Improve existing therapies: This includes reducing side effects, improving efficacy, enhancing patient compliance (e.g., once-daily dosing), or developing new delivery methods.

• Enhance patient quality of life and treatment outcomes: Beyond simply treating disease, the aim is to allow patients to live fuller, healthier lives.

• Advance personalized medicine: Tailoring treatments to individual genetic profiles or disease characteristics to maximize efficacy and minimize adverse effects.

Scope of Drug Discovery

• Small molecule drugs: Traditionally the most common type, these are chemical compounds with low molecular weight (e.g., aspirin, statins, most oral medications). They are often able to cross cell membranes to reach intracellular targets.

• Biologics: Large, complex molecules derived from living organisms, including proteins, monoclonal antibodies, vaccines, and cell therapies. They typically target extracellular proteins or cell surface receptors.

• Gene therapies: Advanced therapeutic products that aim to treat or prevent diseases by modifying or replacing faulty genes, or by introducing new genes into a patient's cells (e.g., CRISPR-Cas9-based therapies).

• Therapeutic areas: Research spans a vast array of diseases, including cancer (oncology), cardiovascular diseases, neurological disorders, infectious diseases, autoimmune conditions, rare genetic disorders, and metabolic diseases.

• Examples: Aspirin (small molecule); Monoclonal antibodies like Adalimumab (Humira) (biologics).

The Drug Development Timeline

• Average timeline: Approximately $10-15\text{ years}$ from the initial discovery of a promising compound to its approval and market release, reflecting the extensive testing required.

• Key phases:

  1. Basic research: Fundamental scientific inquiry into disease mechanisms.

  2. Drug discovery: Identifying and optimizing potential therapeutic compounds.

  3. Preclinical studies: In vitro (test tube) and in vivo (animal) testing for safety and initial efficacy.

  4. Clinical trials: Human testing in multiple phases (Phase 0, I, II, III).

  5. Regulatory review: Evaluation by regulatory bodies like the FDA or EMA.

  6. Post-market surveillance: Ongoing monitoring of safety and efficacy after approval.

• Emphasis: This is a long-term, multi-stage, and inherently complex process requiring significant resources and perseverance.

Investment and Risk

• Average cost to develop a new drug: Estimates range from $\$1\text{ billion}$ to $\$2\text{ billion}$ or more, including the cost of failed projects, making it one of the most capital-intensive industries.

• High failure rates: Only about $1/10{,}000\text{ compounds}$ that enter the discovery pipeline make it to market (roughly $0.01\%$ success rate), with many failing during preclinical or clinical stages due to toxicity or lack of efficacy.

• Risk factors: Include scientific uncertainty (unpredictable biological responses), stringent regulatory hurdles (evolving safety standards), technical challenges (manufacturing complexity), and intense market competition.

• Strategic implication: Robust pipelines and diverse portfolios are crucial for pharmaceutical companies to mitigate risks and ensure long-term viability and innovation.

Stakeholders in Drug Discovery

• Pharmaceutical companies: Driving large-scale R&D and commercialization efforts.

• Biotechnology firms: Often pioneers in novel therapeutic modalities like biologics and gene therapies.

• Government agencies: Providing funding for basic research, setting regulatory standards, and purchasing drugs for public health programs.

• Patients: The ultimate beneficiaries, increasingly involved in informing research priorities and trial design.

• Advocacy groups: Representing patient interests, raising awareness, and funding research for specific diseases.

• Academic institutions: Performing fundamental research, identifying new targets, and training the scientific workforce.

• (Note: Stakeholders interact across the entire pipeline, from basic research to regulation and access, forming a complex ecosystem.)

Role of Academia

• Fundamental research: Academia primarily conducts basic research into disease mechanisms, biological pathways, and potential drug targets, often publishing findings that lay the groundwork for drug discovery.

• Development of new technologies and methodologies: Innovating new screening techniques, analytical tools, and drug delivery systems.

• Training of future scientists and researchers: Educating and mentoring the next generation of experts for both academia and industry.

• Collaborations with industry: Engaging in technology transfer, licensing agreements, and joint research projects to bridge the gap between basic science and commercial development.

• Example: Candocuronium iodide (originally Chandonium Iodide or HS-310); a neuromuscular-blocking agent; recognition for contributors (e.g., Padma Shri Prof. Harkishan Singh, Panjab University), highlighting the academic origins of key discoveries.

Role of Pharmaceutical Industry

• Large-scale drug discovery and development programs: Possessing the financial, infrastructure, and human resources required for extensive R&D.

• Translate basic research into therapies: Taking academic insights and developing them into viable, marketable drug candidates.

• Resources for extensive clinical trials and regulatory processes: Funding and managing the large-scale, multi-phase human trials and navigating complex global regulatory pathways.

• Manufacturing and distribution of approved drugs: Ensuring quality-controlled production and global supply chains for widespread patient access.

• Continuous investment in R&D: Reinvesting profits into future treatments to maintain innovation and address evolving health needs.

Role of Regulatory Agencies

• Ensure safety and efficacy of new drugs (e.g., FDA in the US, EMA in Europe, CDSCO in India): Their core mission is to protect public health by rigorously evaluating all aspects of a drug's profile.

• Establish guidelines for drug development and clinical trials: Providing clear regulations and standards that developers must adhere to, from preclinical testing to post-marketing surveillance.

• Review and approve new drug applications: Conducting thorough assessments of submitted data packages (NDAs, BLAs) before granting market authorization.

• Post-market surveillance for long-term safety: Continuously monitoring drugs once on the market to detect rare or long-term adverse effects (pharmacovigilance).

• Balance thorough evaluation with timely access to new treatments: Agencies often employ accelerated approval pathways or orphan drug designations to speed up access for life-threatening conditions while maintaining high safety standards.

Ethical Considerations

• Patient safety in clinical trials: Paramount importance, ensuring minimal risks, clear protocols, and robust monitoring for adverse events.

• Informed consent and protection of vulnerable populations: Ensuring participants fully understand risks and benefits, especially for children, pregnant women, or those with impaired decision-making capacity.

• Equitable access to new medicines: Addressing disparities in drug availability and affordability globally, especially for life-saving treatments.

• Pricing and affordability of drugs: A contentious issue balancing pharmaceutical companies' R&D costs and profit motives with public health needs and government budgets.

• Balancing profit motives with public health needs: Ensuring that the pursuit of commercial success does not compromise ethical standards or neglect diseases affecting underserved populations.

• Ethical use of animals in preclinical research: Adhering to the 3Rs (Replace, Reduce, Refine) principle for animal welfare.

• Data privacy: Protecting personal health information collected during clinical trials and post-market surveillance.

Drug Discovery Domains (Interdisciplinary Nature)

• Chemistry: Medicinal chemists design and synthesize new compounds, focusing on structure-activity relationships, lead optimization, and intellectual property.

• Biology: Molecular and cell biologists elucidate disease mechanisms, identify novel drug targets (e.g., specific proteins, pathways), and develop assays for screening.

• Pharmacology: Pharmacologists study drug effects on biological systems, mechanisms of action, dose-response relationships, and pharmacokinetics/pharmacodynamics (PK/PD).

• Medicine: Clinicians translate discoveries into clinical applications, design and execute clinical trials, and provide patient care.

• Data science: Bioinformaticians and data scientists analyze large datasets (genomic, proteomic, clinical), build predictive models, and apply machine learning for target identification, drug design, and trial optimization.

• Collaboration is key to success: Effective integration of expertise from all these domains is essential for navigating the complex drug discovery pipeline.

• Related field: Toxicology (assessing safety and adverse effects) is crucial throughout the process.

Technological Advancements

• Genomics and proteomics: High-throughput sequencing and protein analysis help identify novel disease targets, biomarkers, and enable personalized medicine approaches.

• High-throughput screening (HTS): Automated robotic systems rapidly test thousands to millions of compounds against biological targets, dramatically accelerating hit identification.

• Structure-based drug design (SBDD): Utilizing 3D structures of proteins and ligands (obtained via X-ray crystallography, Cryo-EM, NMR) to rationally design and optimize targeted therapies with improved binding affinity and selectivity.

• Artificial intelligence (AI) and machine learning (ML): Employed for predicting drug properties, optimizing molecular structures, identifying new targets, analyzing clinical trial data, and accelerating many aspects of drug discovery from lead generation to clinical development.

• Organ-on-a-chip: Microfluidic cell culture devices that mimic human physiology and organ functions, providing more accurate in vitro models for preclinical drug testing and reducing reliance on animal models.

• Gene editing technologies (e.g., CRISPR-Cas9): Enable precise modification of genes, opening new avenues for understanding disease and developing gene therapies.

Success Stories

• HIV/AIDS: Once a fatal diagnosis, the development of highly active antiretroviral therapy (HAART) revolutionized treatment, transforming the condition into a manageable chronic disease.

• Imatinib (Gleevec): A groundbreaking targeted therapy that selectively inhibits the BCR-ABL tyrosine kinase, revolutionizing the treatment of chronic myeloid leukemia (CML) and significantly improving patient survival rates.

• Hepatitis C: The development of direct-acting antiviral (DAA) agents has led to curative treatments for most genotypes of Hepatitis C virus, a disease previously associated with chronic liver damage and cancer.

• CAR-T cell therapy: A revolutionary form of immunotherapy where a patient's T cells are genetically engineered to express chimeric antigen receptors (CARs) to target and destroy cancer cells, offering breakthroughs in certain blood cancers.

Drug Discovery Successes (Selected Therapies)

• Paclitaxel (Taxol): A chemotherapy drug derived from the Pacific yew tree, widely used for various cancers.

• Vinblastine (Velban): Another plant-derived alkaloid (from Catharanthus roseus), used in chemotherapy.

• Imatinib (Gleevec): As mentioned, a targeted therapy for CML and other cancers.

• Doxorubicin (Adriamycin): An anthracycline antibiotic used in cancer chemotherapy.

• Nilotinib (Tasigna): A second-generation tyrosine kinase inhibitor, also used for CML, particularly in cases of imatinib resistance.

• Topotecan (Hycamtin): A topoisomerase inhibitor used to treat several types of cancer.

• Erlotinib (Tarceva): A tyrosine kinase inhibitor targeting EGFR, used in non-small cell lung cancer and pancreatic cancer.

Thalidomide: Lessons from Failures

• 1954–1956: Thalidomide was introduced as a sedative and later widely established for treating morning sickness due to its perceived clinical safety.

• Animal studies initially indicated a lack of acute toxicity, contributing to its widespread acceptance at the time.

• 1960: Reports of peripheral neuropathy (nerve damage) began to emerge after long-term use in adults.

• 1962: Thalidomide was tragically withdrawn from the market due to its potent teratogenic effects, causing severe birth defects (phocomelia and other deformities) in over 10,000 affected children, often referred to as "Thalidomide babies."

• Regulatory standards for safety and efficacy testing were significantly improved globally as a direct result. This included mandatory assessment for teratogenicity (ability to cause birth defects) and rigorous clinical trial oversight.

• Reassessment of placental protection theories: The tragedy revealed that the human placenta did not entirely protect a fetus from drug exposure, emphasizing the need for robust developmental toxicity testing.

• Revealed importance of drug chirality: Subsequent research demonstrated that Thalidomide exists as two enantiomers: the (R)-isomer has sedative effects, while the (S)-isomer is largely responsible for the teratogenic effects. This distinction was not understood at the time of its initial use.

• Conclusion: The Thalidomide tragedy made pharmaceutical companies and regulatory bodies recognize chirality as a critical checkpoint in drug development, leading to stricter guidelines for testing and marketing chiral drugs, often requiring the development of single enantiomers.

Summary

• Drug discovery is a systematic, multi-stage, and highly regulated process aimed at ensuring the development of safe and effective treatments for diseases.

• The journey from discovery-to-market is protracted, involving rigorous preclinical and multi-phase clinical testing, coupled with extensive regulatory oversight to safeguard public health.

• Key stakeholders include pharmaceutical and biotechnology industries, government regulatory agencies, academic researchers, and increasingly, patients and advocacy groups, with a growing influence from advanced computational methods like AI and precision medicine.

• Ethical considerations remain central to every stage, encompassing patient safety, equitable accessibility, drug affordability, and regulatory compliance, shaping the responsible advancement of medical science.

Think About It

• How might drug discovery priorities differ between developed and developing countries, considering prevalent diseases and resource availability?

• What ethical considerations arise from these differences in priorities and access to cutting-edge treatments?

Further Reading (Selected)

• Mohs, R.C.; Greig, N.H. Drug discovery and development: Role of basic biological research. Alzheimer's Dement (N.Y.). 2017;3(4):651-657. doi:10.1016/j.trci.2017.10.005.

• Hughes, J.P.; Rees, S.; Kalindjian, S.B.; Philpott, K.L. Principles of early drug discovery. Br J Pharmacol. 2011;162(6):1239-1249. doi:10.1111/j.1476-5381.2010.0112